Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240319 | 1.00 | ESR2 (0.32) | ESR2SOS1 | |
| SCHEMBL29918620 | 0.83 | CRHR1 (0.31) | ESR2 | |
| SCHEMBL25396743 | 0.79 | ALDH1A1 (0.38) | SOS1 | |
| SCHEMBL30122319 | 0.75 | CA1 (0.31) | — | |
| SCHEMBL29861403 | 0.70 | HSD17B10 (0.33) | SOS1 | |
| SCHEMBL23326744 | 0.70 | HSD17B10 (0.33) | SOS1 | |
| SCHEMBL29861748 | 0.70 | CYP1A2 (0.33) | ESR2SOS1 | |
| SCHEMBL23326640 | 0.70 | CYP1A2 (0.33) | ESR2SOS1 | |
| SCHEMBL31425998 | 0.67 | KDM4E (0.32) | — | |
| SCHEMBL15287612 | 0.64 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED | 2022-10-13 | — | — | US | disclosed |
| WO-2022212531-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324862-A1 | PYRIDOPYRIMIDINONE COMPOUNDS | RSU1, SOST, CCNA1 | ESR2 615/4885SOS1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.